Bonviva Effective as a Once-Monthly Oral Formulation for Osteoporosis - RxChemist.co.uk continues its lead in the provision of the newest prescription medication to its customers. Ibandronate (ibandronic acid) once monthly (Bonviva 150mg) received a positive opinion on granting a marketing authorisation from the European Medicines Evaluation agency in June 2005. The licensed indication for ibandronate once monthly will be the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.
International Press Release Publishing for free in 15 languages across 22 countries
Press Releases
Google-Suche:
 

Blog blogger.com

You are not logged in, so we don't know your blog. Please fill in the data to access your blog at blogger.com. The entered information will be stored for this session.
Username
Password
Blog-URL
 
Title of your post
Text of your post
SUBCATEGORIES
Women's Health
 
 
Pressreleases by authors
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z